oral glp 1 agonist With FDA approval of Wegovy pill, new era of GLP-1 weight loss drugs begins Peptide GLP-1 receptor agonists: From

Chronic weight management: GLP-1s have gained recent popularity for their use in chronic weight management

GLP-1a: Going beyond traditional use

doi:10.1007/s00125-002-0818-5 123

placebo), most of them (liraglutide, semaglutide SC, dulaglutide, albiglutide, and efpeglenatide) have also demonstrated a reduction in MACE with respect to placebo, while weekly exenatide or oral semaglutide showed a tendency to reduce MACE

In addition to their metabolic effects, these medications act on other bodily systems involved in the physiopathology of various neurological and psychiatric disorders

Conclusions GLP-1 RAs have emerged as novel agents in managing CVD, extending their utility beyond glycemic control in T2DM